Product Details
Synonyms
PCSK9, FH3, HCHOLA3, LDLCQ1, NARC1, PC9
Source
Human PCSK9 Protein, C-terminal domain truncated, His Tag (PC9-H52H7) is expressed from human 293 cells (HEK293). It contains AA Gln 31 -His 449 (Accession # Q8NBP7-1).
Predicted N-terminus: Gln 31 & Ser 153
Request for sequenceMolecular Characterization

Other Tags and Version Biotin & Other Labeled Version
This protein carries a polyhistidine tag at the C-terminus. The protein has a calculated MW of 13.8 kDa & 33.5 kDa. The protein migrates as 15 kDa and 33 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation. This protein variant lacks the C-terminal domain (CRD), which is essential for its LDLR binding and degradation functions.
Endotoxin
Less than 0.01 EU per μg by the LAL method / rFC method.
Purity
>90% as determined by SDS-PAGE.
Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
Shipping and Storage
This product is shipped at ambient temperature.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
ACRO Quality Management System
Kunden haben auch angesehen
Data Display
SDS-PAGE

Human PCSK9 Protein, C-terminal domain truncated, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90% (With Star Ribbon Pre-stained Protein Marker).
User Reviews Publish Comment

FAQ
- Product
What key experimental conditions should be considered for PCSK9–LDLR binding assays?
It is recommended to perform PCSK9–LDLR binding assays under acidic conditions, as the interaction exhibits higher activity in acidic environments compared to neutral ones. Reference: Effects of pH and Low Density Lipoprotein (LDL) on PCSK9-dependent LDL Receptor Regulation.
Background Introduction
Frontier Progress
- English Name:
Proprotein convertase subtilisin kexin type 9
- Category:
- Listed Drugs Count:
8 Details
- Clinical Drugs Count:
35 Details
- Highest R&D Stage:
Approved



















